HCWB
HCW Biologics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.22
P/S
11.05
EV/EBITDA
-0.48
DCF Value
$-8.37
FCF Yield
-2233.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-300.7%
Operating Margin
-24299.0%
Net Margin
-41117.2%
ROE
1121.0%
ROA
-90.9%
ROIC
-128.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $27.0K | $-13.6M | $-1.77 |
| FY 2025 | $54.2K | $-22.3M | $-10.63 |
| Q3 2025 | $15.6K | $-4.6M | $-2.02 |
| Q2 2025 | $6.5K | $-1.9M | $-6.79 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.79
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.